87 results about "Orciprenaline" patented technology

In a first aspect, the present invention relates to a process for producing a stable, injectable solution with low content of noradrenaline, which includes dissolving noradrenaline and optionally an excipient in deoxygenated or degassed water, filtrating the resulting noradrenaline solution in a nitrogen current, distributing the solution in a nitrogen current, and sterilization, preferably hot. The invention further provides a stable, injectable solution with low content of noradrenaline, substantially free of anti-oxidizing and preservative agents, as well as uses thereof in the medical and pharmaceutical fields.

The compounds of the present invention are represented by the following 2,5-methano- and 2,5-ethano-tetrahydrobenzazepine derivatives having formula (I):

where the carbon atom designated * is in the R or S configuration when n is 1 and the substituents X and R¹-R⁷ are as defined herein.

The invention belongs to the technical field of clinical biological sample detection. The invention specifically relates to a technology for detecting catecholamine and metabolites thereof in blood plasma, in particular to a method for detecting catecholamine and metabolites thereof (epinephrine, norepinephrine, dopamine, metanephrine, normetaneprine and 3-methoxytyramine) by high-throughput liquid chromatography-tandem mass spectrometry. The method comprises the steps of standard solution preparation, sample treatment, sample detection and formula calculation. The method can be used for simultaneously detecting six substances including catecholamine and metabolites thereof, and has the advantages of high accuracy, high sensitivity, high specificity, small required sample volume, simple sample pretreatment, good tolerance and the like.

The present invention is directed to phenylaminopropanol derivatives of formula (I): or a pharmaceutically acceptable salt thereof; wherein: the dotted line between Y and Z represents an optional double bond; the dotted line between the two R4 groups represents an optional heterocyclic ring of 4 to 6 ring atoms that may be formed between the two R4 groups, together with the nitrogen through which they are attached; Y is N, CR6, or C=O; Z is N, CR7, CR5, or C(R5)2; R2 is aryl substituted with 0-3 R1 or heteroaryl substituted with 0-3 R1; R3 is H or C1-C4 alkyl; n is an integer form 0 to 4; x is an integer from 1 to 2; and the other substituents are defined in the claims; compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromylagia syndrome, nervous system disorders, and combinations thereof, particularly those conditions selected form the group consisting of major depressive disorder, vasomotor symptoms, stress and urge urinary incontinence, fibromyalgia, pain, diabetic neuropathy, and combinations thereof.

The aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepine derivative compounds of the present invention are represented by formulae 1(A-D) having the following structure: where the substituents X and R¹-R⁸ are as defined herein.

The invention provides alkyne compounds as well as a preparation method and an application thereof and belongs to the technical field of extraction of alkyne compounds and effective ingredients of traditional Chinese medicines. Specifically, new compounds I, II and IV as well as a reported compound III are obtained from dried roots of Umbeliferae Bupleurum Radix Bupleuri through extraction and separation. In-vitro monoamine neurotransmitter reuptake inhibition experiments are conducted on the compounds, results indicate that the compounds I, II, III and IV have inhibition effects on reuptake of NA (noradrenaline), have the inhibition effects equivalent to that of positive control drug desipramine and have different degrees of inhibition effects on reuptake of 5-HT (5-hydroxytryptophan). The four compounds have anti-depression activity and are expected to be developed into drugs or prodrugs for preventing and treating anti-depression related diseases.

The invention discloses new medicinal application of 3,6'-disinapoyl sucrose (DISS), in particular the application of the 3,6'-disinapoyl sucrose (DISS) in preparing a product for treating tristimania. The 3,6'-disinapoyl sucrose (DISS) has better therapeutic effect on treating the tristimania caused by various reasons and obvious anti-depression activity to a pharmacological depression model, and the anti-depression activity of the 3,6'-disinapoyl sucrose is relative to the enhancement of the functions of 5-hydroxytryptamine (5-HT) and noradrenergic (NE) nerves. The DISS has no central excitation or inhibitive action within the range of an effective dosage of anti-depression.

The invention provides bupropion analogue compounds capable of inhibiting the reuptake of one or more monoamines. The compounds may selectively bind to one or more monoamine transporters, including those for dopamine, norepinephrine, and serotonin. Such compounds may be used to treat conditions that are responsive to inhibition of the reuptake of monoamines, including addiction, depression, and obesity.

The invention discloses an autism diagnosis kit, the autism diagnosis kit comprises a reagent for detecting the intestinal microbial metabolite concentration, wherein the intestinal microbial metabolite comprises at least one of acetic acid, tyramine, histamine, gamma-aminobutyric acid, dihydroxyphenylalanine and norepinephrine. The acetic acid content and the score of the severity degree of the autism are in a negative correlation relationship; the contents of tyramine, histamine, gamma-aminobutyric acid, dihydroxyphenylalanine and norepinephrine are respectively in positive correlation withthe severity of autism, and the autism is diagnosed through the intestinal microbial metabolite level of an excrement sample, so that the kit has relatively high accuracy. Therefore, the intestinal microorganism metabolite combination level of a subject can be used as an index for screening and diagnosing autism under the conditions of scientific research and clinical application.

The invention belongs to the technical field of detection and in particular relates to a pheochromocytoma diagnostic kit and a using method thereof. According to the technical scheme in the invention, normetanephrine (NMN), metanephrine (MN), 3-methyltyramine (3-MT) and creatinine (Cr) in random urine can be detected by adopting high performance liquid chromatography, and pheochromocytoma is diagnosed by utilizing a ratio of the previous three to-be-detected substances to a peak area of the creatinine. The kit disclosed by the invention comprises the following reagents: a sample pretreatment reagent, a standard stock solution and a mobile phase. The pheochromocytoma is diagnosed by directly utilizing the ratio of the three to-be-detected substances to the peak area of the creatinine, and the pheochromocytoma diagnostic kit is simple in reagents, low in price, convenient to use and high in cost performance.

Chemical syntheses and medical uses of novel inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, for the treatment and/or management of psychotropic disorders, anxiety disorder, generalized anxiety disorder, depression, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, hot flashes, senile dementia, migraine, hepatopulmonary syndrome, chronic pain, nociceptive pain, neuropathic pain, painful diabetic retinopathy, bipolar depression, obstructive sleep apnea, psychiatric disorders, premenstrual dysphoric disorder, social phobia, social anxiety disorder, urinary incontinence, anorexia, bulimia nervosa, obesity, ischemia, head injury, calcium overload in brain cells, drug dependence, and/or premature ejaculation are described.

The invention discloses a composition for regulating emotion factors and improving sub-health and a preparation method thereof. According to the composition, oligopeptide 1 and various plant compositions are used as main components, and through scientific material selection and reasonable matching, endogenous "happy hormone" monoamine neurotransmitters (e.g. 5-hydroxytryptamine, norepinephrine and dopamine) and peptide neurotransmitters such as P substances, catecholamine and betaenorphine of a human body can be regulated through skin absorption, so that the composition has a good application prospect. Then according to traditional Chinese medicine principle of soothing liver to regulating the Qi, pressure is released, metabolism is enhanced, Qi and blood are unblocked, local microcirculation is improved and inflammation is eliminated andstasis is removed; besides, through mutual cooperation, sub-health states such as anxiety, depression, insomnia and the like caused by emotional problems are effectively relieved.

The embodiment of the invention provides a death prediction method and system for a sepsis-related acute kidney injury patient, equipment and a medium, and belongs to the technical field of medical care information. The method specifically comprises the steps of training an XGBOOST algorithm through a sample data set, and establishing a prediction model; collecting the urine volume, the maximum value of urea nitrogen, the noradrenaline injection rate, the maximum value of anion gap, the maximum value of creatinine, the maximum value of red blood cell distribution width, the minimum value of international standardization ratio, the maximum value of heart rate, the maximum value of body temperature, the minimum value of oxygen uptake fraction, the stroke state, the minimum value of creatinine, the minimum Glasgow coma scale and a diabetes state of a target person; and inputting the key information data set into a prediction model to obtain a prediction result. According to the scheme, the machine learning algorithm is used for learning, the prediction model is established, then the collected key information data set is input into the prediction model, the prediction result is obtained, and the prediction efficiency and accuracy are improved.

Provided are ready to use drip bags of dilute noradrenaline having improved stability in terms of subvisible particle formation.